Table 3.

Efficacy outcome measurements for the included studies

Study ID	Groups	N	ORR (%) (95% CI)	Median PFS, months (95% CI)	DoR, months (95% CI)	DCR, n (%)
Li et al. 2022 [18]	TS + CT CT	33 33	60.61% 33.33%	12.12 (8.50-13.91) 7.65 (3.88–10.52)	N/A N/A	27 (81.82) 19 (57.58)
Lu et al. 2021 [19]	TS + CT CT	223 111	57.4 (50.6–64.0) 36.9 (28.0–46.6)	9.7 (7.7–11.5) 7.6 (5.6–8.0) Hazard ratio = 0.65 (0.46–0.90), p = 0.004	8.5 (6.80–10.58) 6.0 (4.99–not estimable)	N/A N/A
Wang et al. 2021 [20]	Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP)	120 119 121	73 (63.6–80.3) 75 (66.0-82.3) 50 (40.4–58.8)	7.6 (6.0-9.8) 7.6 (5.8–11.0) 5.5 (4.2–5.7) A versus C: Hazard ratio = 0.52 (0.37–0.74), p < 0.001 B versus C: Hazard ratio = 0.48 (0.34–0.68), p < 0.001	8.2 (5.0-not estimable) 8.6 (6.3-not estimable) 4.2 (2.8–4.9)	N/A N/A
Zhou et al. 2022 [21]	TS CT	535 270	22.6 (19.1–26.4) 7.1 (4.3–10.8)	4.2 (3.9–5.5) 2.6 (2.2–3.8) Hazard ratio = 0.63 (0.53–0.75), p < 0.0001	13.5 (8.5–19.6) 6.0 (2.1–7.2)	298 (55.70) 114 42.20

Abbreviations: TS: tislelizumab; CT: chemotherapy; PTX: paclitaxel; CBP: carboplatin; ORR: objective response rate; PFS: progression-free survival; DoR: duration of response; DCR: disease control rate; CI: confidence interval; N/A: not available